CURRENT PROBLEMS IN CANCER

医学 肿瘤学

  • 影响指数:2.365
  • 中科院分区:医学 4区 医学 3 区
  • 审稿周期:平均1.33月
  • 自引率:15.3%
  • 录取率:33.33%
  • ISSN:2190-572X
  • 发刊频率:暂无数据
  • 年文章数:454
  • 国人占比:26.03%
  • 期刊网址:点击查看
  • 研究方向:肿瘤;生信
  • 期刊攻略
  • IF变化趋势
  • 期刊占比
  • 最新文章

期刊简介

3 BIOTECH杂志暂不明确行业,暂不明确子行业的级别不明杂志

收稿要求

暂无数据

建议

杂志水平一般,也很冷门,关注人少,审稿周期可能也不一定快,如果文章质量不佳,或时间不紧的话,可以考虑考虑。

Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders.

DOI:10.1016/j.currproblcancer.2022.100864

发表时间:2022 May 2

作者:Kumar R;Chan A;Bandikatla S;Ranjan S;Ngo P

Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.

DOI:10.1016/j.currproblcancer.2022.100875

发表时间:2022 Jun 1

作者:Capitanio U MD;Fallara G MD;Raggi D MD;Nocera L MD;Larcher A MD;Belladelli F MD;Rowe I PhD;Briganti A MD,PhD;Salonia A MD,PhD;Karakiewicz P MD;Montorsi F MD;Martini A MD;Necchi A MD

Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities.

DOI:10.1016/j.currproblcancer.2022.100867

发表时间:2022 May 21

作者:Bailey S;Wang Q;Kong CY;Stone K;Veluswamy R;Bates SE;Smith CB;Wisnivesky JP;Sigel K

Non-bacterial cystitis secondary to pembrolizumab: A case report and review of the literature.

DOI:10.1016/j.currproblcancer.2022.100863

发表时间:2022 May 3

作者:He X;Tu R;Zeng S;He Z;Liu S;Fang Y

Evaluation and external validation of minor lymphatic pelvic pathway for distant metastases in cervical cancer patients treated with concurrent chemoradiotherapy.

DOI:10.1016/j.currproblcancer.2022.100876

发表时间:2022 Jun 1

作者:Thephamongkhol K;Korpraphong P;Muangsomboon K;Sitathanee C;Lertkhachonsuk AA;Phongkitkarun S;Srirattanapong S;Prapruttam D;Bridhikitti J;Dendumrongsup T;Alisanant P;Amornwichet N;Khorprasert C;Sasiwimonphan K;Tanprasertkul C;Dhanachai M;Patumanond J;Setakornnukul J

公众号